What's Happening?
Better Medicine, an AI-powered diagnostic startup, has raised $7 million to commercialize its radiology tools. The funding includes a $1.1 million pre-seed round led by Soulmates Ventures and a $2.9 million grant from the European Innovation Council. The company aims to address the growing demand for radiology services amid a shortage of professionals by deploying AI models that assist in detecting and measuring oncological findings in CT scans. Its flagship product, BMVision Kidney, has received CE certification as a Class IIa medical device, demonstrating significant time savings and high detection rates in clinical evaluations.
Why It's Important?
The funding and expansion of Better Medicine's AI-powered tools are crucial in addressing the global shortage of radiologists and the increasing volume of scans. By automating lesion detection and measurement, the technology enhances efficiency and accuracy in radiology departments, potentially improving patient outcomes. The company's focus on early cancer detection and freeing doctors from repetitive tasks aligns with broader healthcare goals of improving diagnostic capabilities and reducing workload pressures. As the company prepares for FDA clearance and U.S. clinical pilots, its technology could significantly impact radiology practices worldwide.
What's Next?
Better Medicine plans to use the new funding to expand its product portfolio and commercial rollout across Europe, while preparing for FDA clearance in the U.S. The company aims to launch clinical pilots tailored to meet FDA study requirements, potentially paving the way for broader adoption of its AI tools in American healthcare systems. As the technology gains traction, it may lead to increased collaborations with hospitals and healthcare providers, further integrating AI into standard radiology practices and enhancing diagnostic capabilities.
